Companion Diagnostics: Page 3

Foundation Medicine, Relay Therapeutics to collaborate

By LabPulse.com staff writers

RLY-4008 is a work-in-progress oral small-molecule inhibitor of FGFR2, which is part of a set of proteins that can mutate into diseases such as cholangiocarcinoma, according to Foundation Medicine. Under the collaboration, FoundationOne CDx would be used to help clinicians identify patients with FGFR2 mutations and select those who could benefit from treatment with RLY-4008.

September 11, 2022

Illumina to present oncology research abstracts at ESMO 2022

By LabPulse.com staff writers

The abstracts underscore the value of next-generation sequencing (NGS) and Illumina's oncology assays for cancer research and patient care, the firm said.

September 7, 2022

FYR, Medicover partner to expand into North America

By LabPulse.com staff writers

The collaboration will support pharmaceutical companies with clinical trial assay development and implementation, codevelopment of novel diagnostic technologies, and companion diagnostic testing services.

August 30, 2022

Myriad Genetics CDx nabs expanded coverage in Japan

By LabPulse.com staff writers

BRACAnalysis classifies a patient's clinically significant DNA sequence variations in the germline BRCA1 and BRCA2 genes.

August 25, 2022

Roche CDx assay receives CE label expansion

By LabPulse.com staff writers

The announcement came after the conclusion of a Phase III study sponsored by Genentech that observed the efficacy of Tecentriq in treating patients with NSCLC.

August 23, 2022

Pillar Biosciences colon cancer test gets Chinese approval

By LabPulse.com staff writers

The clearance adds China to the company's other markets for the test, which include the U.S. and Europe.

August 21, 2022

FYR Dx, Medicover partner on assay, tech development

By LabPulse.com staff writers

The firms plan to support pharmaceutical companies with clinical trial assay development and implementation, codevelopment of novel diagnostic technologies, and companion diagnostic testing services.

August 16, 2022

Kronos, Invivoscribe to develop CDx for entospeltinib

By LabPulse.com staff writers

The CDx will screen for the NPM1 mutation, which is present in approximately one-third of all patients with AML.

August 16, 2022

Thermo Fisher, Guardant Health get approval for NSCLC CDx

By LabPulse.com staff writers

Enhertu is an HER2-directed antibody drug conjugate being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

August 11, 2022

FDA approves label expansion for Roche CDx

By LabPulse.com staff writers

The label expansion follows the FDA approval in April 2021 of the Ventana MMR RxDx Panel as the first IHC predictive test to identify endometrial carcinoma patients eligible for treatment with the anti-PD1 immunotherapy Jemperli (dostarlimab-gxly).

August 10, 2022

BD, Labcorp to develop flow cytometry CDx

By LabPulse.com staff writers

Specifically, the agreement creates a framework for BD and Labcorp Drug Development to collaborate on flow cytometry-based CDx opportunities with pharmaceutical partners.

August 8, 2022

CAP issues guideline to improve immunotherapy treatment

By Dexter Johnson

The CAP guideline is evidence-based and joins a small number of testing methods based on both the methodology and the status of the biomarker -- i.e., microsatellite testing and deficient mismatch repair process assessment. This stands in contrast to previous guidelines that focused on the cancer type or tumor origin.

August 4, 2022

Previous Page

Page 3 of 12

Next Page